Literature DB >> 26183746

Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

Shiro Kimbara1, Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, Yoshinori Imamura, Naomi Kiyota, Toru Mukohara, Atsushi Fukunaga, Masahiro Oka, Chikako Nishigori, Hironobu Minami.   

Abstract

Necrolytic migratory erythema (NME) is a classical paraneoplastic symptom observed in patients with pancreatic glucagonoma. We report a 46-year-old Japanese woman with glucagonoma who presented with mucocutaneous manifestations 1 year prior to the diagnosis of the pancreatic neoplasm with multiple liver metastases. She was treated with octreotide long-acting release, a somatostatin analog, which resulted in a dramatic improvement of NME within 2 weeks after the start of treatment. Increased awareness of NME may avoid unnecessary delay in the diagnosis of pancreatic glucagonoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 26183746     DOI: 10.1007/s12328-014-0471-9

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  16 in total

1.  Necrolytic migratory erythema with carcinoma of the pancreas.

Authors:  D S Wilkinson
Journal:  Trans St Johns Hosp Dermatol Soc       Date:  1973

Review 2.  Pancreatic endocrine tumors.

Authors:  Kjell Oberg
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

3.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 4.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

Review 5.  Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases.

Authors:  J Soga; Y Yakuwa
Journal:  J Hepatobiliary Pancreat Surg       Date:  1998

6.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors:  Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

7.  Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer.

Authors:  Karl Y Bilimoria; Mark S Talamonti; Stephen F Sener; Malcolm M Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  J Am Coll Surg       Date:  2008-06-30       Impact factor: 6.113

Review 8.  New strategies for advanced neuroendocrine tumors in the era of targeted therapy.

Authors:  Mei Dong; Alexandria T Phan; James C Yao
Journal:  Clin Cancer Res       Date:  2012-02-15       Impact factor: 12.531

9.  Localization of pancreatic endocrine tumors by endoscopic ultrasonography.

Authors:  T Rösch; C J Lightdale; J F Botet; G A Boyce; M V Sivak; K Yasuda; N Heyder; L Palazzo; H Dancygier; V Schusdziarra
Journal:  N Engl J Med       Date:  1992-06-25       Impact factor: 91.245

10.  Necrolytic migratory erythema: clinicopathologic study of 13 cases.

Authors:  Ramon M Pujol; Chin-Yao Eric Wang; Rokea A el-Azhary; W P Daniel Su; Lawrence E Gibson; Arnold L Schroeter
Journal:  Int J Dermatol       Date:  2004-01       Impact factor: 2.736

View more
  1 in total

1.  Glucagonoma and the glucagonoma syndrome.

Authors:  Xujun Song; Suli Zheng; Gang Yang; Guangbing Xiong; Zhe Cao; Mengyu Feng; Taiping Zhang; Yupei Zhao
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.